Screener
Kestra Medical Technologies KMTS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Kestra Medical Technologies in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Kestra Medical Technologies’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 5:16 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001193125-26-303397
| Line item | Year Ended April 30, 2026 | Year Ended April 30, 2025 |
|---|---|---|
| Amortization (accretion) of premiums (discounts) on securities, net | (106) | — |
| Interest paid-in-kind | — | 855 |
| Amortization of debt discounts and issuance costs | 1,874 | 1,400 |
| Share-based compensation expense | 33,644 | 24,270 |
| Non-cash lease expense | 326 | 416 |
| Deferred income tax expense | 166 | 64 |
| Change in fair value of warrant liabilities | (2,673) | 2,648 |
| Changes in operating assets and liabilities: |
Item 16. Form 10-K Summary.
FAQ
- What is Kestra Medical Technologies's stock-based comp?
- Kestra Medical Technologies (KMTS) reported stock-based comp of $10.3M in Q1 2026.
- How has Kestra Medical Technologies's stock-based comp changed year-over-year?
- Kestra Medical Technologies's stock-based comp decreased by 53.8% year-over-year, from $22.31M to $10.3M.
- What is the long-term trend for Kestra Medical Technologies's stock-based comp?
- Over 2 years (2024 to 2026), Kestra Medical Technologies's stock-based comp has grown at a 375.5% compound annual growth rate (CAGR), from $1.49M to $33.64M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Kestra Medical Technologies's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude